One year of adjuvant trastuzumab, preferentially given upfront with a taxane as part of an anthracycline–taxane containing chemotherapy, is currently considered standard therapy for treating early-stage breast cancer. The long-awaited full publication of the BCIRG-006 trial now establishes the TCH (docetaxel, carboplatin, trastuzumab) regimen as an additional option with a distinct safety profile.boxed-text
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
21 December 2011
In the version of this article initially published online the author's name in the citation line was spelled incorrectly. The error has been corrected for the HTML and PDF versions of the article.
References
Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273–1283 (2011).
Harbeck, N., Ewer, M. S., De Laurentiis, M., Suter, T. M. & Ewer, S. M. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann. Oncol. 22, 1250–1258 (2011).
Untch, M. et al. Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline taxane based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44). [Abstract S3-1] In 33rd Annual San Antonio Breast Cancer Symposium (San Antonio, Texas, 2010).
Gennari, A. et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J. Natl Cancer Inst. 100, 14–20 (2008).
Huober J. et al. Effect of neoadjuvant anthracycline taxane based chemotherapy in different biological breast cancer phenotypes: overall results from the Gepar Trio study. Breast Cancer Res. Treat. 124, 133–140 (2010).
Di Leo, A. et al. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur. J. Cancer. 44, 2791–2798 (2008).
McArthur, H. L. et al. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer. doi: 10.1002/cncr.26171 (2011).
Kelly, C. M. et al. Coping with uncertainty: T1a, bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann. Oncol. 22, 2387–2393 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
N. Harbeck has received honoraria from lectures and consulting from Genentech, Roche and Sanofi-Aventis.
Rights and permissions
About this article
Cite this article
Harbeck, N. Increasing therapy options for HER2-positive early breast cancer. Nat Rev Clin Oncol 9, 10–12 (2012). https://doi.org/10.1038/nrclinonc.2011.193
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.193
This article is cited by
-
Correction: Breast cancer: increasing therapy options for HER2-positive early breast cancer
Nature Reviews Clinical Oncology (2012)
-
HER2-specific T lymphocytes kill both trastuzumab-resistant and trastuzumab-sensitive breast cell lines in vitro
Chinese Journal of Cancer Research (2012)
